(IRTC) iRhythm Technologies - Ratings and Ratios
Patch Monitor, Mobile Telemetry, ECG Software, Continuous Monitoring
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 39.7% |
| Value at Risk 5%th | 60.1% |
| Relative Tail Risk | -8.02% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.63 |
| Alpha | 81.06 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.513 |
| Beta | 0.810 |
| Beta Downside | 0.753 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.15% |
| Mean DD | 22.10% |
| Median DD | 22.46% |
Description: IRTC iRhythm Technologies November 07, 2025
iRhythm Technologies, Inc. (NASDAQ: IRTC) is a U.S.-based digital health firm that designs, develops, and commercializes prescription-only, patch-based cardiac monitoring solutions (Zio Monitor, Zio XT, Zio AT) that record continuous ECG data for up to 14 days and feed the recordings into its proprietary Zio ECG Utilization Software for automated arrhythmia detection.
The company’s core revenue stream comes from ambulatory cardiac monitoring services-both long-term (up to 14 days) and short-term telemetry-delivered to physicians and health systems across the United States. In FY 2023, iRhythm reported ≈ $470 million in total revenue, representing a ~ 12 % year-over-year increase driven primarily by higher utilization of its Zio AT platform and expanding payer contracts.
Key sector drivers include the growing prevalence of atrial fibrillation (projected to affect > 12 million U.S. adults by 2030) and the shift toward outpatient diagnostics that are reimbursed under Medicare’s “remote cardiac monitoring” codes (e.g., CPT 93306). iRhythm’s collaboration with Verily Life Sciences aims to accelerate next-generation AF screening, potentially widening its addressable market beyond the current ~ 30 % of cardiology referrals that use ambulatory monitoring.
From a financial-risk perspective, iRhythm’s gross margin has stabilized around 55 % after a 2022-23 cost-optimization program, but the company remains sensitive to changes in reimbursement policy and competitive pressure from emerging wearables (e.g., Apple Watch ECG) that could erode its payer-centric moat.
For analysts looking to deepen their valuation framework, a quick review of ValueRay’s proprietary risk-adjusted cash-flow model for IRTC can surface hidden upside or downside scenarios that aren’t captured in consensus estimates.
IRTC Stock Overview
| Market Cap in USD | 5,504m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2016-10-20 |
| Return 12m vs S&P 500 | 90.3% |
| Analyst Rating | 4.62 of 5 |
IRTC Dividends
Currently no dividends paidIRTC Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 18.46% |
| CAGR/Max DD Calmar Ratio | 0.31 |
| CAGR/Mean DD Pain Ratio | 0.84 |
| Current Volume | 1010k |
| Average Volume | 456.2k |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (-51.5m TTM) > 0 and > 6% of Revenue (6% = 42.2m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 11.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 75.88% (prev 94.25%; Δ -18.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 73.9m > Net Income -51.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (32.6m) change vs 12m ago 4.20% (target <= -2.0% for YES) |
| Gross Margin 70.35% (prev 67.83%; Δ 2.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.76% (prev 61.56%; Δ 12.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.98 (EBITDA TTM -15.2m / Interest Expense TTM 13.2m) >= 6 (WARN >= 3) |
Altman Z'' -0.39
| (A) 0.54 = (Total Current Assets 680.0m - Total Current Liabilities 146.9m) / Total Assets 995.2m |
| (B) -0.81 = Retained Earnings (Balance) -809.0m / Total Assets 995.2m |
| (C) -0.04 = EBIT TTM -39.2m / Avg Total Assets 952.5m |
| (D) -0.93 = Book Value of Equity -808.7m / Total Liabilities 873.3m |
| Total Rating: -0.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 40.84
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 0.57% = 0.29 |
| 3. FCF Margin 4.61% = 1.15 |
| 4. Debt/Equity 6.01 = -2.50 |
| 5. Debt/Ebitda -31.40 = -2.50 |
| 6. ROIC - WACC (= -13.26)% = -12.50 |
| 7. RoE -51.06% = -2.50 |
| 8. Rev. Trend 97.83% = 7.34 |
| 9. EPS Trend 51.24% = 2.56 |
What is the price of IRTC shares?
Over the past week, the price has changed by -4.99%, over one month by -7.86%, over three months by +6.07% and over the past year by +117.94%.
Is IRTC a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IRTC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 219.9 | 31.3% |
| Analysts Target Price | 219.9 | 31.3% |
| ValueRay Target Price | 183.8 | 9.7% |
IRTC Fundamental Data Overview November 17, 2025
P/S = 7.8336
P/B = 45.1517
Beta = 1.101
Revenue TTM = 702.6m USD
EBIT TTM = -39.2m USD
EBITDA TTM = -15.2m USD
Long Term Debt = 648.8m USD (from longTermDebt, last quarter)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 733.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 477.4m USD (from netDebt column, last quarter)
Enterprise Value = 5.67b USD (5.50b + Debt 733.0m - CCE 565.2m)
Interest Coverage Ratio = -2.98 (Ebit TTM -39.2m / Interest Expense TTM 13.2m)
FCF Yield = 0.57% (FCF TTM 32.4m / Enterprise Value 5.67b)
FCF Margin = 4.61% (FCF TTM 32.4m / Revenue TTM 702.6m)
Net Margin = -7.32% (Net Income TTM -51.5m / Revenue TTM 702.6m)
Gross Margin = 70.35% ((Revenue TTM 702.6m - Cost of Revenue TTM 208.3m) / Revenue TTM)
Gross Margin QoQ = 71.09% (prev 71.17%)
Tobins Q-Ratio = 5.70 (Enterprise Value 5.67b / Total Assets 995.2m)
Interest Expense / Debt = 0.45% (Interest Expense 3.28m / Debt 733.0m)
Taxrate = -0.46% (negative due to tax credits) (24.0k / -5.19m)
NOPAT = -39.4m (EBIT -39.2m * (1 - -0.46%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.63 (Total Current Assets 680.0m / Total Current Liabilities 146.9m)
Debt / Equity = 6.01 (Debt 733.0m / totalStockholderEquity, last quarter 121.9m)
Debt / EBITDA = -31.40 (negative EBITDA) (Net Debt 477.4m / EBITDA -15.2m)
Debt / FCF = 14.73 (Net Debt 477.4m / FCF TTM 32.4m)
Total Stockholder Equity = 100.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.17% (Net Income -51.5m / Total Assets 995.2m)
RoE = -51.06% (Net Income TTM -51.5m / Total Stockholder Equity 100.8m)
RoCE = -5.23% (EBIT -39.2m / Capital Employed (Equity 100.8m + L.T.Debt 648.8m))
RoIC = -5.26% (negative operating profit) (NOPAT -39.4m / Invested Capital 748.4m)
WACC = 8.00% (E(5.50b)/V(6.24b) * Re(9.0%) + D(733.0m)/V(6.24b) * Rd(0.45%) * (1-Tc(-0.00)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.01%
[DCF Debug] Terminal Value 70.16% ; FCFE base≈32.4m ; Y1≈25.2m ; Y5≈16.2m
Fair Price DCF = 8.00 (DCF Value 257.8m / Shares Outstanding 32.2m; 5y FCF grow -26.42% → 3.0% )
EPS Correlation: 51.24 | EPS CAGR: 30.81% | SUE: 0.96 | # QB: 1
Revenue Correlation: 97.83 | Revenue CAGR: 21.61% | SUE: 2.12 | # QB: 4
Additional Sources for IRTC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle